Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMBD-501 in advanced HER3-expressing solid tumors
NCT06956690Phase 2Recruiting
- Sponsor
- Hummingbird Bioscience
- Start
- Dec 2025
- Primary completion
- Jul 2027
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 2
01
Overview
A Phase 2 trial of hmbd-501 in melanoma, non-small cell lung cancer (NSCLC), breast cancer, pancreatic ductal adenocarcinoma (PDAC), gastric cancer (GC), sponsored by Hummingbird Bioscience. Started Dec 2025; status: recruiting.
02
Drugs
hmbd-501
03
Conditions
melanomanon-small cell lung cancer (NSCLC)breast cancerpancreatic ductal adenocarcinoma (PDAC)gastric cancer (GC)
Beyond the preview
Go deeper on NCT06956690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06956690.